Sorafenib and Erlotinib in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
6 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Purchase Cancer Group - Paducah
Paducah, Kentucky, United States
- Erlanger Cancer Center at Erlanger Hospital - Baroness
Chattanooga, Tennessee, United States
- Baptist Regional Cancer Center at Baptist Riverside
Knoxville, Tennessee, United States
- Vanderbilt-Ingram Cancer Center
Nashville, Tennessee, United States
- Vanderbilt-Ingram Cancer Center - Cool Springs
Nashville, Tennessee, United States
- Vanderbilt-Ingram Cancer Center at Franklin
Nashville, Tennessee, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Oct 2008
- Primary completion
- 30 Apr 2011
- Completion
- 30 Nov 2012
- Last update posted
- 25 Jun 2014
- Registered enrollment
- 37
- Registry id
- NCT00837876
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.